Pfizer Launches Expanded Access Program For CCR5 Antagonist Maraviroc
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer will begin enrolling HIV patients in the next “few months” and will recruit investigators that have not previously worked in expanded access.
You may also be interested in...
Pfizer’s Selzentry Wins FDA Approval For HIV
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.
Pfizer’s Selzentry Wins FDA Approval For HIV
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.
Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues
FDA’s Antiviral Drugs Advisory Committee will also assess whether existing data supports accelerated approval for the first-in-class HIV therapy.